Insider Buy: QNCX Chief Adds Shares & Warrants Ahead of 2030

Q: How many QNCX shares did CEO Dirk Thye purchase on 18 June 2025?

He bought 150,944 common shares according to the Form 4.

Q: What price did Dirk Thye pay for the newly acquired QNCX shares?

The filing lists a purchase price of $1.20 per share .

Q: What is Dirk Thye’s total direct ownership in QNCX after the transaction?

Following the acquisition, Thye directly owns 994,885 common shares .

Q: Did the QNCX CEO acquire any derivative securities?

Yes. He received warrants for 150,944 shares with a $1.20 exercise price expiring on 18 June 2030.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Quince Therapeutics (QNCX) filed a Form 4 disclosing that CEO, CMO and Director Dirk Thye increased his equity stake on 18 June 2025.

Thye acquired 150,944 common shares at $1.20 (Transaction Code A) and simultaneously received warrants for an additional 150,944 shares with the same $1.20 exercise price, expiring 18 June 2030. Following the transactions, his direct beneficial ownership rose to 994,885 common shares, an increase of roughly 15 %. The disclosed cash outlay for the common-share purchase is approximately $181 000; the warrants were priced at $0.125 each.

No shares were sold, and the filing does not indicate the use of a Rule 10b5-1 trading plan. These insider purchases may signal management confidence, though the dollar value is modest relative to typical market-moving thresholds.

Positive

CEO insider purchase: Dirk Thye acquired 150,944 common shares at $1.20, increasing his direct stake by roughly 15 %.
Long-dated warrants: He also obtained warrants for 150,944 shares exercisable at $1.20 until 18 June 2030, underscoring long-term commitment.

Negative

None.

Insights

TL;DR: CEO adds 15 % to holding; positive signal but limited monetary size.

The Form 4 shows Dirk Thye buying 150,944 shares plus identical warrants at $1.20. While the purchase value (~$181k) is small versus Quince’s likely market cap and liquidity, the 15 % boost to the CEO’s direct stake and the five-year warrants align his interests more closely with shareholders. Absence of any sales removes overhang fears. Historically, insider buying at market price is a bullish indicator, yet the size suggests only incremental impact. Overall, directionally positive but not a game-changer.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Thye Dirk

Role CEO and CMO

Type	Security	Shares	Price	Value
Grant/Award	Warrants	150,944	$0.125	$19K
Grant/Award	Common Shares	150,944	$1.20	$181K

Holdings After Transaction: Warrants — 150,944 shares (Direct); Common Shares — 994,885 shares (Direct)

Footnotes (1)

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/23/2025 - 08:43 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thye Dirk

(Last)

(First)

(Middle)

C/O QUINCE THERAPEUTICS, INC.

611 GATEWAY BLVD., SUITE 273

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Quince Therapeutics, Inc. [ QNCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO and CMO

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	06/18/2025		A		150,944	A	$1.2	994,885	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Warrants	$1.2	06/18/2025		A		150,944		06/18/2025	06/18/2030	Common Shares	150,944	$0.125	150,944	D

Explanation of Responses:

	/s/ Dirk Thye	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

How many QNCX shares did CEO Dirk Thye purchase on 18 June 2025?

He bought 150,944 common shares according to the Form 4.

What price did Dirk Thye pay for the newly acquired QNCX shares?

The filing lists a purchase price of $1.20 per share.

What is Dirk Thye’s total direct ownership in QNCX after the transaction?

Following the acquisition, Thye directly owns 994,885 common shares.

Did the QNCX CEO acquire any derivative securities?

Yes. He received warrants for 150,944 shares with a $1.20 exercise price expiring on 18 June 2030.

Was the trade executed under a Rule 10b5-1 trading plan?

The Form 4 includes a checkbox for Rule 10b5-1 trades, but it is not marked; no such plan is indicated.